PUBLISHER: GlobalData | PRODUCT CODE: 1410893
PUBLISHER: GlobalData | PRODUCT CODE: 1410893
Endoscopic Hemostasis Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 is built to visualize quantitative market trends within Endoscopy Devices therapeutic area.
The model discusses in detail the impact of COVID-19 on Endoscopic Hemostasis Devices market for the year 2020 and beyond. Endoscopic Hemostasis is a technique employed in the management of Gastrointestinal (GI) bleeding and often acts as the first line of therapy. Since hemostasis treatment using these devices are performed by means of an endoscope, it is known as Endoscopic Hemostasis.
The indications of endoscopic hemostasis technique include various upper and lower gastrointestinal bleeding diseases. Upper GI bleeding mainly includes peptic ulcer bleeding and variceal bleeding while diverticular bleeding and benign anorectal bleeding are the most common etiologies for hospital admissions with lower GI bleeding. Other causes include esophagitis, mallory-weiss syndrome, dieulafoy's lesion, post-polypectomy bleeding, vascular ectasia, radiation proctitis, inflammatory bowel disease and delayed bleeding occurring after endoscopic mucosal resection.
These devices are generally classified into mechanical devices (clips, ligation devices, suturing devices, stents), injection devices (injection needles), thermal devices (hemostatic probes, hemostatic forceps, heater probe, argon plasma coagulation, radiofrequency ablation, and cryotherapy) and topical devices (hemostatic spray).
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Endoscopic Hemostasis Devices and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Boston Scientific Corp, ConMed Corp, Cook Group Inc, ERBE Elektromedizin GmbH, Olympus Corp, Steris Plc, Micro-Tech Nanjing Co Ltd, Integra LifeSciences Holdings Corp, Medline Industries Inc, Diversatek Inc, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable
Not Applicable
Not Applicable